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Abstract
Background: Healthcare providers-related disparities in adherence to the treatment plan among lymphoma patients
are found even in a universal healthcare system, but the mechanism remains unclear. We investigated the association
between the type of care center and the relative dose intensity and determined whether it persists after adjustment for
patients’ recruitment differences.
Methods: Prospective observational cohort study of 294 patients treated with standard protocols for diffuse large
B-cell lymphoma (DLBCL) in teaching or community public hospitals or in private centers in the French Midi-Pyrénées
region from 2006–2013. To test our assumptions, we used multinomial and mixed-effect logistic models progressively
adjusted for patients’ biomedical characteristics, socio-spatial characteristics and treatment-related toxicity events.
Results: Patients treated using standard protocols in the teaching hospital had more advanced stage and poorer initial
prognosis without limitation regarding the distance from the residence to the care center. Patients’ recruitment profile
across the different types of care center failed to explain the difference in relative dose intensity. Low relative dose
intensity was less often observed in teaching hospital than elsewhere.
Conclusion: We showed that even in a universal healthcare system, disparities in the management of DLBCL patients’
do exist according to the types of care center. A main issue may be to find and diffuse the reasons of this benefit in
cancer management in the teaching hospital to the other centers.
Keywords: Lymphoma, Center-related management disparity, Relative dose intensity, Observational cohort, French
current practice
Key message
In this study in French current practice on 294 lymphoma
patients treated with the standard R-CHOP or R-CHVP
protocols, low relative dose intensity was less often
observed in teaching hospital than elsewhere. This sug-
gests that even in a universal healthcare system, disparities
in the management of diffuse large B-cell lymphoma
patients’ do exist according to the types of care center.
Background
Little is known about the mechanisms behind survival
disparities according to many non-medical factors
including age, ethnic group, socioeconomic status
(SES), and place of residence observed in hematological
malignancies. [1–10] Among lymphoma, one potential
mechanism emerges from the results of studies among
Hodgkin lymphoma (HL) [11] and non-Hodgkin Lymph-
oma (NHL) [12–14] showing that socioeconomic factors,
place of residence, and distance to the care center may
affect access to treatment and treatment selection which
was in turn related to survival. Another potential mechan-
ism emerges from the results of studies dealing with the
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type of care provider and its consequence on survival. A
population-based study of the Nebraska Lymphoma Study
Group found a higher risk of death among high-risk
lymphoma patients treated in rural university or
community-based providers and urban community based
provider compared to urban university-based providers.
[15] More recently, in a study based on an ongoing French
regional cohort of diffuse large B cell lymphomas
(DLBCL) treated with R-CHOP (rituximab, cyclophospha-
mide, doxorubicin, vincristine, prednisone) or RCHOP-
derived regimens, the results showed that care facility type
may influence overall survival and patients management.
In this study, patients cared for in the regional public
teaching hospital were more likely to receive the dose of
chemotherapy initially planned by the medical team, i.e.
the relative dose intensity (RDI). [16] The ability to ensure
a high RDI may be seen as a marker of high quality of
care, as it is known to be associated with higher survival.
[17, 18] To go further in the mechanisms linking the
healthcare providers to survival, it remains uncertain
whether better high RDI is only linked to a difference in
patients’ recruitment profiles across the various types of
treatment provider or whether it also reflects real differ-
ences in cancer care and management practices. Indeed,
in France the secondary care in oncology consists of
private funding centers which can be nonprofit or for-
profit and nonprofit public funding centers encompassing
small community public hospitals to larger university
affiliated hospitals. Moreover, in the French healthcare
system, based on a universal access to care, patients are
able to choose freely the hospital they wish to go to.
Thus, although all patients may have access to special-
ized care, some patients could miss out on the best
possible treatment because of high preference for prox-
imity centers. [19] This, with the fact that the academic
or high-volume center are unlikely to be located
outside large urban areas, may also lead to differences
in the recruitment profiles of patients in the different
types of care facility.
In the present study, we rule out both access to
treatment and treatment selection issues by consider-
ing a sample of DLBCL patients all treated by standard
protocols R-CHOP or R-CHVP (rituximab, cyclophos-
phamide, doxorubicin, etoposide, prednisone) each
21 days which constitutes a sample of patients globally
homogeneous regarding the treatment their received
[20, 21]. We aim to investigate whether and why RDI
varies according to the types of care facility wherein
patients were treated. Using data from French com-
mon practice, we try to disentangle the expression of
patients’ recruitment disparities between centers from
the expression of differences in centers’ features, which
are assumed to be quite homogeneous for each type of
care facility.
Method
Study design and population
The data were taken from the AMARE cohort, an
ongoing prospective cohort of DLBCL patients in the
Midi-Pyrénées region, the largest region of mainland
France. This regional cancer network made up exclusively
of cancer patients, including hematological malignancies,
dictates that all e-medical files are systemically screened
by disease-specific boards of experts during a multidiscip-
linary team meeting (MTM). Patients were identified by
their presentation in MTM and were included in the
AMARE cohort if they received first-line treatment for
DLBCL with R-CHOP or R-CHOP-like regimens from
November 2006 without age restriction, in the main
centers covered by the regional cancer network: the public
funding regional teaching hospital, five public funding
community centers, and five private funding for-profit
centers. The exclusion criteria were: central nervous
system involvement, HIV infection, solid organ transplant-
ation or previously documented indolent NHL. All
patients signed an informed consent before inclusion in
this network. The study was approved by the local ethics
committee of the Toulouse teaching hospital. In the
present study, we focused exclusively on patients treated
by R-CHOP or R-CHVP which represented one on two
patients treated for DLBCL of the initial AMARE cohort
per types of care facility.
Data collection
Data were collected by one person through direct examin-
ation of administrative and medical records of the 336
patients treated from November 2006–November 2013
(last follow-up in September 2014) who received the
standard R-CHOP or R-CHVP protocols. During the
follow-up, information was gathered regarding treatment-
related events and vital status, including the date of the
events. Care centers were pooled by type of care center:
the public funding teaching hospital (Toulouse public
funding University Hospital (UH)), the public funding
community hospitals (CH), and the private funding for-
profit hospitals (PH). Although these study deals with the
data from 11 hospitals, we assume that the inter-facility
type variability of the centers features are greater than the
intra-facility type variability.
We collected patients’ biomedical characteristics at
diagnosis: age (continuous and in quartile); comorbidity
(none or at least one among chronic or viral hepatitis,
cardiovascular or metabolic disease, autoimmune disease
or cancer); gender; the Ann Arbor stage, divided into
localized (Ann Arbor stage I or II) or advanced (Ann
Arbor stage III or IV); the ECOG performance status
(PS) (PS of 0–4, with 1 being good and 4 being poor)
[22] and the serum lactate dehydrogenase concentration
(normal or elevated (>1)). We preferred using direct
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values of these parameters rather than crude categorization
as IPI [23, 24] or NCCN-IPI [25] scores that may introduce
undesirable colinearity. We also noted the chemotherapy
regimen at treatment initiation, which was described in
detail elsewhere. [21, 26–28] Regarding patients’ socio-
spatial characteristics, we used quintiles of the Euro-
pean ecological deprivation index (EDI) aggregated at
the intra-municipalities level, built from patients’
residential addresses at diagnosis as a proxy of their
individual socioeconomic status. [29] We assessed the
travel distance by the road based on the fastest route in
kilometers between the patient’s residence and their
care center and between the patient’s residence and the
teaching hospital coded in tertile to avoid making
assumptions on any threshold. For each patient, the
relative dose intensity (RDI) as described by Epelbaum
et al. [30], was assessed using the ratio between the
dose intensity received and that initially planned at the
treatment initiation. In this study, we calculated RDI
for the principal drugs, i.e. cyclophosphamide and
doxorubicin. After excluding patients who deceased or
had tumor progression during the first-line treatment,
patients who did not receive the whole initially planned
dose intensity (RDI < 100 %) were considered as having
low RDI. Sensitivity analyzes were done using the con-
tinuous RDI value. Data regarding treatment-related
toxicity events were documented by the total number
of hospitalization days for toxicity over the first-line
treatment period, but the dates of events were not
available. The information regarding the cause conces-
sion was not available.
Statistical analysis
To study the factors influencing patients’ repartition
across the different types of care center, we built a multi-
variate multinomial logistic regression model by fixing
the UH as the reference center to analyze the factors
associated with being cared for in CH (model 1a) and in
PH (model 1b). Then, we used multivariate logistic
regression models with mixed effects to test for any
center effect using the center as a random intercept. We
tested the influence of the types of care providers on the
probability of having low RDI without adjustment
(model 2a) and after progressively adjusting for patients’
biomedical characteristics (model 2b), socio-spatial char-
acteristics (model 2c) and treatment-related toxicity
events (model 2d). Our models included all variables
associated with these outcomes in bivariate analyzes at
the threshold of 0.2 (data not shown). The models were
systematically adjusted for age, sex and socioeconomic
status. All analyzes were done by using STATA release 12
(StataCorp LP, College Station, TX, USA). The cartog-
raphy of patients and center distribution was performed
using R [31] and data from the French National Institute
of Geography.
Results
In this study, we analyzed 294 patients who were alive at
the treatment initiation and had complete data, which
was about 87 % of the total number of the 336 patients
treated by R-CHOP or R-CHVP. Compared to the
included patients, those who were not included in the
study belonged more often to the oldest age class, had
more often advanced stage tumor, had poorest initial
prognoses, and presented more often hospitalization for
treatment-related toxicity and poor RDI. However they
were evenly spread through the types of care facility
(data not shown). The flowchart is given in Fig. 1. The
characteristics of patients, disease and cancer manage-
ment by types of care center are presented in Table 1.
Overall, the UH cared for younger patients with poorer
initial prognosis, PH cared for patients with less comor-
bidity and better performance status, and CH cared for
patients with more comorbidities and poorer perform-
ance status. Lastly, CH and PH tended to care for
patients living in their vicinity, three out of four patients
lived within a roughly 40 km radius, whereas patients
cared for in the UH may have come from farther away.
Moreover, patients cared for in PH or CH almost never
lived nearer to the UH than the center where they were
cared for. The map of patients’ geographical distribution
around the center where they are cared for is presented
in supplemental file in the Fig. 2 which illustrates
patients’ preferences for proximity centers and the
capability of the UH to recruit both patients living near
or far from the center.
Table 2 presents the factors associated with being
cared for somewhere else than the UH. Compared with
patients in the UH, those in CH were more likely to
have degraded performance status, and better initial
prognosis. These patients also tended to live in a less
favorable socioeconomic area, more specifically they
tended to live more often in favored (p = 0.033) areas
than in highly favored areas. Compared with patients in
the UH, those in PH were more likely to have earlier
stage tumor, and to live less than 40 km from their care
center. These patients also tended to have degraded
performance status but this was not statistically signifi-
cant with an alpha risk fixed at 5 % (p-value = 0.072),
Table 3 shows that being treated using the standard
R-CHOP or R-CHVP protocols in UH rather than else-
where was associated with lower rate of low RDI. After
accounting successively for patients’ biomedical charac-
teristics, their socio-economical characteristics and dis-
tance to care center, low RDI was more frequent in PH
than in UH (model 2c, OR [95 % CI] = 3.3 [1.5; 7.1])
and CH (model 2c, OR [95 % CI] = 2.6 [1.2; 5.6]). The
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adjustment for hospitalization for toxicities altered the
OR associated with CH which became no more statisti-
cally significant (model 2d, OR [95 % CI] = 1.9 [0.8; 4.4]).
We have tested the center effect using a random intercept
which was not presented as its variance was smaller than
10−8 after adjustment for the type of care provider. This
may translate the fact the center-related variations in the
probability of low RDI was completely explained by the
type of the care center. In addition, the models showed
that an advanced stage at diagnosis and at least one day of
hospitalization for toxicity were more likely to result in
low RDI. No effects were noted for age, comorbidity,
initial prognosis, social deprivation level, and distance to
center. Similar results were obtained in sensitivity analyzes
using RDI as a continuous variable (data not shown).
Discussion
This study, based on an ongoing cohort of DLBCL
patients treated in the French Midi-Pyrénées region,
shows an independent beneficial effect on RDI in the
UH. PH, CH and UH cared for populations with differ-
ent biomedical and socio-spatial characteristics. The
former centers were more likely to treat patients living
in their vicinity roughly within a 40 km radius. Patients
treated in UH had more advanced stage and poorer ini-
tial prognosis without limitation regarding the distance
from the residence to the care center. Patients’ recruit-
ment profile across the different types of care providers
failed to explain the difference in RDI between UH and
PH or CH. In this study among patients only treated
with standard protocols, low RDI was less often
observed in UH than elsewhere. This may translate a
potentially greater quality in cancer care and manage-
ment specific to this center, despite the universal health-
care system setting.
One of the main limitations of this study is that we
cannot generalize our results to the national level and
to other French teaching hospitals in general. How-
ever, this study dealt with the fourth more densely
populated regions in France according to the French
National Institute of Statistic and Economics Studies
(INSEE) [32] and the largest region of mainland
France in terms of size. In addition, as is often
observed in the rest of the country, regional health-
care is heterogeneously distributed around large urban
area wherein multidisciplinary team meetings held in
the UH centralize decisions regarding the manage-
ment of both in- and outpatients, especially those
needing intense treatment. At last, we excluded 42
patients from our analyzes because of missing data,
decease or tumor progression during the treatment.
These patients were evenly spread through the three
center types. The comparison of the characteristics of
included and excluded patients suggested that our
sample overrepresented younger patients with less
advanced stage tumor, better initial prognosis, less
often hospitalization for toxicity and more often high
RDI. The patients we studied would thus have a more
favorable profile than those usually encountered in
the current practice. We assume that caring patients
Fig. 1 Flowchart
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with less favorable profile necessitate more discussion
within the medical team and consequently it would
be more affected by center-related disparity in cancer
management.
This study has also several strengths. Few studies have
explored the role of care provider types on treatment
adherence in common practice in a universal healthcare
system setting. We used a large (n = 294) DLBCL popula-
tion homogeneously treated with the standard R-CHOP
or R-CHVP protocols. Moreover, we collected data on
biomedical and socio-spatial characteristics of patients,
including the distance from residence to the reference
center and to the care center where patients went, and
treatments; this allowed us to study the effect of the types
of care center among patients receiving the a same stand-
ard treatment.
Studies in solid tumors have already documented the
influence of the care center characteristics on cancer
Table 1 Patients’ characteristics and treatment adherence according to the care centers. N = 294
Total PH CH UH
n % n % n % n %
Patients’ characteristics
Gender Male 153 52 51 62 34 49 68 48
Female 141 48 31 38 36 51 74 52
Age (tercile) t1 (until 59y) 88 30 24 29 20 29 44 31
t2 (60y to 72y) 156 53 40 49 37 53 79 56
t3 (73y and more) 50 17 18 22 13 19 19 13
Comorbidity None 117 40 36 44 26 37 55 39
At least 1 177 60 46 56 44 63 87 61
Performance status (0 / 1–4) Normal 234 80 67 82 45 64 122 86
Degraded 60 20 15 18 25 36 20 14
Social deprivation index Highly fav. 63 21 18 22 10 14 35 25
Fav. 43 15 14 17 13 19 16 11
Intermediate 68 23 22 27 18 26 28 20
Dep. 74 25 13 16 19 27 42 30
Highly dep. 46 16 15 18 10 14 21 15
Nearest care center UH 119 40 8 10 0 0 111 78
Other 175 60 74 90 70 100 31 22
Distance (km) to the care center Mean (SD) 38 (59) 23 (30) 28 (29) 51 (76)
Med [q1-q3] 20 [7; 47] 12 [4;30] 24 [7; 39] 23 [10; 68]
Distance (km) to the teaching hospital Mean (SD) 87 (74) 123 (62) 119 (42) 51 (76)
Med [q1-q3] 75 [22; 137] 128 [69;176] 113 [81;155] 23 [10; 71]
Disease characteristics
Stage I/II 123 42 44 54 26 37 53 37
III/IV 171 58 38 46 44 63 89 63
LDH: lactate dehygrogenase Normal 163 55 50 61 49 70 64 45
Elevated 131 45 32 39 21 30 78 55
B symptoms Absence 255 87 75 91 55 79 125 88
Presence 39 13 7 9 15 21 17 12
Cancer management
Hospitalization for toxicity None 240 82 71 87 44 63 125 88
At least 1 day 54 18 11 13 26 37 17 12
Relative dose intensity (RDI) Mean (SD) 0.97 (0.10) 0.95 (0.11) 0.95 (0.12) 0.98 (0.08)
Med [q1-q3] 1 [1; 1] 1 [0.9; 1] 1 [0.9; 1] 1 [1; 1]
Relative Dose Intensity (RDI) RDI = 100 % 229 78 58 71 50 71 121 85
RDI < 100 % 65 22 24 29 20 29 21 15
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care and patients outcomes. [33] Some evidence mainly in
the United States and Northern European countries
supports the benefit of being cared for in high-volume or
academic hospitals, such as improved survival in lung [34]
and colorectal cancers, [35] and improved survival and
adherence to the guidelines in ovarian [36] and breast can-
cers. [37, 38] Regarding hematological malignancies, re-
sults from a population-based study in Nebraska showed a
benefit of being cared for in urban university-based
centers on survival among high risk lymphoma patients.
[15] In more recent studies, the type of care center was
also linked to overall survival showing a benefit of being
treated in high volume hospital among acute myeloid
leukemia [39] and DLBCL. [16] However, the underlying
mechanism remains unclear. In the present study, we
showed that higher RDI observed in the UH was not due
to patient’s characteristics or treatment. This may suggest
differential quality of care according to the center. The
real stake is to identify what characteristics of the center
may contribute to higher RDI in order to disseminate to
the other centers and to ensure to all patients, whatever
the center where are cared for, the best possible manage-
ment of their cancer. Indeed, an organizational interven-
tion has been implemented since 2006 among DLBCL
patients treated in the UH of Midi-Pyrénées: an oncology-
certified nurse systematically calls the patients during the
treatment phase and collects clinical and biological obser-
vations, which are forwarded to the oncologist to enhance
the care management and adherence to the treatment
plan. [40] Presently, the efficacy in reducing low RDI and
the medico-economic evaluation of this nurse navigator
procedure will be formally tested in a non-randomized-
controlled study among several French teaching hospi-
tals. We assume that such intervention may participate
substantially to the mechanisms behind the higher RDI
observed in the UH. In other clinical settings, studies
have already given evidences of the benefits of nurse
navigator interventions on cancer patients care man-
agement. [41–44] A possible solution may be to ensure
such service for all patients across the region. However,
other explanations are conceivable. For the past several
years, studies have supported the existence of a non-
compliance issue in medical oncology, pointing out the
influence of physicians and care providers on adherence
to the treatment plan was better in academic settings
for both conventional [45] and targeted chemotherapy.
[46] However, how the types of care providers may
influence physician non-adherent behavior remains
unclear. With regard to our study, we can rule out an
effect of any lack of knowledge and weakness in clin-
ician training as, regardless of the center where they
practice, most of the clinicians have been trained by the
Hematology Department of the UH. In addition, they
regularly attend regional education sessions and national
meetings which take place at least yearly. Another explan-
ation might reside in the fact that reduction in treatment
intensity outside academic settings may reflect more cau-
tious care behavior among clinicians. Indeed, compared to
Fig. 2 Patients overall spatial distribution by care providers
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clinicians in teaching hospitals, they may more frequently
face frailer patients and limited facilities such as emer-
gency or imaging units available 7 days a week and 24 h a
day and therefore be inclined to reduce dose-intensity.
Conversely, in the UH, the availability of facilities might
encourage clinicians to not reduce dose-intensity which
would be associated, at least in part, with an increase of
hospitalization for toxicities. However, our results showed
higher RDI in UH than PH even after controlling for
hospitalization for toxicities. Moreover, hospitalizations for
toxicities were more frequent in CH than elsewhere and
adjustment for this variable altered the OR associated with
CH which did not correspond to this explanation. In
addition, the presence of the nurse navigator program in
the UH may also encourage clinician to not reduce dose-
intensity tendencies because it may provide a support to
manage symptoms. This does not mean that the UH effect
we observed is only the manifestation of the nurse
navigator intervention, and we have to question whether
such intervention would have been implemented elsewhere
than in UH and with what outcome. Indeed, the “UH ef-
fect” on RDI we observed in this study may correspond to
the expression of an enabling environment for developing
innovative interventions. But whatever the reason, our re-
sults show differences between care centers that may be the
consequence of different care management as potentially il-
lustrated in UH. This point is major for us because it asks
the question of how to insure the same quality of care
everywhere on the French territory, which is an aim of the
French health system.
Conclusion
This observational study in French common clinical prac-
tice shows that even in a universal healthcare system, dis-
parities do exist in the management of DLCBL patients
treated by standard protocols according to the types of
Table 2 Factors associated with being cared for somewhere other than in the Toulouse public funding University Hospital (UH)
among patients treated by standard regimens (RCHOP or RCHVP) (n = 294)
Being cared for the public funding community
hospitals (CH) instead of in UH
Being cared for in the private funding
for-profit hospitals (PH) instead of in UH
Model 1a Model 1b
OR [95 % CI] p-value OR [95 % CI] p-value
Age (tertile) t1 (until 59y) 1 1
t2 (60y to 72y) 0.9 [0.4; 1.9] 0.777 0.9 [0.4; 1.8] 0.749
t3 (73y and more) 1.3 [0.5; 3.6] 0.586 2.1 [0.8; 5.2] 0.127
Gender Men 1 1
Women 0.9 [0.5; 1.8] 0.818 0.6 [0.4; 1.2] 0.152
Comorbidity None 1 1
At least 1 1.2 [0.6; 2.3] 0.676 0.9 [0.5; 1.7] 0.795
Performance status Normal 1 1
Degraded 4.3 [1.9; 9.5] 0.000 2.2 [0.9; 5.1] 0.072
Distance to the care
center (km)
Up to 13 km 1 1
14 – 41 km 1.5 [0.7; 3.3] 0.296 0.5 [0.2; 1.1] 0.070
At least 42 km 0.5 [0.2; 1.3] 0.158 0.2 [0.1; 0.5] 0.000
Social deprivation index Highly favored 1 1
Favored 3.2 [1.1; 9.4] 0.033 2.0 [0.7; 5.2] 0.182
Intermediate 2.7 [1.0; 7.6] 0.054 1.8 [0.7; 4.5] 0.184
Deprived 2.5 [0.9; 6.7] 0.073 0.7 [0.3; 1.9] 0.519
Highly deprived 2.4 [0.7; 7.5] 0.143 1.6 [0.6; 4.1] 0.370
Stage I/II 1 1
III/IV 0.9 [0.4; 1.7] 0.645 0.5 [0.3; 0.9] 0.026
B symptoms Absence 1 1
Presence 1.6 [0.7; 4.0] 0.271 0.6 [0.2; 1.7] 0.356
Lactate dehydrogenase Normal 1 1
Elevated 0.3 [0.1; 0.6] 0.000 0.6 [0.3; 1.2] 0.145
Global p-values in model 1a age: p = 0.704, social deprivation index: p = 0.226, distance to the care center: p < 0.055; in model 1b age: p = 0.135, social deprivation
index: p = 0.186, distance to the care center: p = 0.001
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care center. Although the fact that the treatment plan of
all patients has been initially discussed in MTM which in-
volves doctors among who most were trained at the same
facility, we found management discrepancies related to
the type of the care facility. Indeed, we found a higher ad-
hesion to the treatment plan associated with being treated
in the regional teaching hospital, not due to differences in
recruited patients or in treatment provided. This suggests
that at least in our study population, attempts at standard-
izing care using a medical outreach team, practice guide-
lines and clinician performance assessments might be not
sufficient to ensure equal access to high-quality care. In
addition, the place that teaching hospitals should occupy
in the care landscape appears to be a critical issue. The
dissemination of innovative organizational interventions
such as for instance the nurse navigator developed for
DLBCL patients in the Toulouse UH to non-academic
centers might improve quality of care.
Abbreviations
CH, public funding community hospital; DLBCL, diffuse large B cells
lymphoma; ECOG, Eastern Cooperative Oncology Group; HIV, human
immunodeficiency virus; HL, Hodgkin Lymphoma; IPI: international
prognostic index; MTM, multidisciplinary team meeting; NCCN, the national
comprehensive cancer network of the United States of America; NHL,
non-Hodgkin Lymphoma; PH, private funding for-profit hospital; PS, ECOG
performance status; R-CHOP, rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone; R-CHVP,rituximab, cyclophosphamide, doxorubicin,
etoposide, prednisone; RDI, relative dose intensity; SES, socio-economical
status; UH, public funding teaching hospital
Table 3 Factors associated with having a low RDI (RDI < 100 %) among DLBCL patients treated with CHOP21/RCHVP (n = 294)
Model 2a Model 2b Model 2c Model 2d
beta [95 % CI] p-value beta [95 % CI] p-value beta [95 % CI] p-value beta [95 % CI] p-value
Age 56 – 65 y 1 1 1
66 to 75y 0.4 [0.2; 0.8] 0.008 0.4 [0.2; 0.8] 0.014 0.4 [0.2; 0.8] 0.010
At least 76y 0.6 [0.2; 1.4] 0.206 0.6 [0.3; 1.5] 0.265 0.6 [0.2; 1.4] 0.246
Gender Men 1 1 1
Women 1.4 [0.8; 2.6] 0.242 1.4 [0.8; 2.6] 0.233 1.4 [0.8; 2.6] 0.251
Comorbidity None 1 1 1
At least 1 1.2 [0.6; 2.2] 0.572 1.2 [0.6; 2.2] 0.653 1.2 [0.6; 2.3] 0.583
Performance status Normal 1 1 1
Degraded 1.5 [0.7; 3.1] 0.310 1.4 [0.7; 3.1] 0.354 1.3 [0.6; 2.9] 0.480
Stage I/II 1 1 1
III/IV 1.4 [0.8; 2.7] 0.282 1.5 [0.8; 2.8] 0.211 1.5 [0.8; 2.8] 0.235
B symptoms Absence 1 1 1
Presence 1.4 [0.6; 3.1] 0.472 1.4 [0.6; 3.2] 0.441 1.2 [0.5; 2.9] 0.626
Lactate dehydrogenase Normal 1 1 1
Elevated 1.2 [0.7; 2.3] 0.491 1.1 [0.6; 2.1] 0.679 1.1 [0.6; 2.0] 0.814
Social deprivation index Highly fav. 1 1
Favored 0.6 [0.2; 1.8] 0.403 0.7 [0.2; 2.0] 0.508
Intermediate 0.7 [0.3; 1.7] 0.387 0.7 [0.3; 1.8] 0.444
Deprived 1.1 [0.5; 2.7] 0.842 1.1 [0.5; 2.8] 0.815
Highly dep. 1.0 [0.4; 2.6] 0.993 1.0 [0.4; 2.6] 0.935
Distance to the care center (km) Up to 13 km 1 1
14 – 40 km 1.0 [0.5; 2.1] 0.995 1.2 [0.6; 2.5] 0.687
At least 41 km 1.6 [0.7; 3.3] 0.266 1.5 [0.7; 3.3] 0.323
Hospitalization for toxicity None 1
At least 1 day 2.8 [1.4; 5.7] 0.006
Type of care center UH 1 1 1 1
CH 2.3 [1.2; 4.6] 0.019 2.2 [1.0; 4.8] 0.039 2.6 [1.2; 5.6] 0.020 1.9 [0.8; 4.4] 0.120
PH 2.4 [1.2; 4.6] 0.010 2.8 [1.4; 5.6] 0.005 3.3 [1.6; 7.1] 0.002 3.3 [1.5; 7.1] 0.002
All the models were adjusted for centre effect using a random intercept which is not presented as its variance in all the models was smaller than 10−8, this may be
interpreted as a random intercept variance not statistically different from zero. Global p-values in model 2a type of care center: p < 0.016; in model 2b age: p = 0.029,
type of care center: p = 0.013; in model 2c age: p = 0.050, social deprivation index: p = 0.709, distance to the care center: p = 0.456, type of care center: p = 0.005; in
model 2d age: p = 0.037, social deprivation index: p = 0.805, distance to the care center: p = 0.612, type of care center: p = 0.009
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